[HTML][HTML] Recent advances in the mechanisms and treatment of immune thrombocytopenia
Primary immune thrombocytopenia is an autoimmune disease associated with a reduced
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
[HTML][HTML] Thrombopoietin receptor agonists: ten years later
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
[HTML][HTML] Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …
Platelet and megakaryocyte roles in innate and adaptive immunity
M Koupenova, AC Livada, CN Morrell - Circulation research, 2022 - Am Heart Assoc
Classically, platelets have been described as the cellular blood component that mediates
hemostasis and thrombosis. This important platelet function has received significant …
hemostasis and thrombosis. This important platelet function has received significant …
Pathogenesis of immune thrombocytopenia
S Audia, M Mahévas, M Samson, B Godeau… - Autoimmunity …, 2017 - Elsevier
Immune thrombocytopenia (ITP) is a rare autoimmune disease due to an abnormal T cell
response, notably supported by splenic T follicular helper cells, that stimulates the …
response, notably supported by splenic T follicular helper cells, that stimulates the …
[HTML][HTML] Emerging concepts in immune thrombocytopenia
M Swinkels, M Rijkers, J Voorberg… - Frontiers in …, 2018 - frontiersin.org
Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts
which presents with an increased bleeding risk. Several genetic risk factors (eg …
which presents with an increased bleeding risk. Several genetic risk factors (eg …
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
MN Saleh, JB Bussel, G Cheng, O Meyer… - Blood, The Journal …, 2013 - ashpublications.org
Patients with chronic immune thrombocytopenia may have bleeding resulting from low
platelet counts. Eltrombopag increases and maintains hemostatic platelet counts; however …
platelet counts. Eltrombopag increases and maintains hemostatic platelet counts; however …
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
J Rodon, MA Carducci, JM Sepulveda-Sánchez… - Clinical Cancer …, 2015 - AACR
Purpose: TGFβ signaling plays a key role in tumor progression, including malignant glioma.
Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ …
Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ …
Immune thrombocytopenia
G Kistangari, KR McCrae - Hematology/Oncology Clinics, 2013 - hemonc.theclinics.com
Immune thrombocytopenia (ITP) is a common hematologic disorder that affects patient of all
ages, genders, and races. Initially known as idiopathic thrombocytopenic purpura, an …
ages, genders, and races. Initially known as idiopathic thrombocytopenic purpura, an …